

Anti-INFa [ST29]

Catalogue number: 151162

Sub-type: Primary antibody

Images:

Contributor

Inventor: Joyce Taylor-Papadimitriou

Institute: Cancer Research UK, London Research Institute: Lincoln's Inn Fields

Images:

Tool details

***FOR RESEARCH USE ONLY**

Name: Anti-INFa [ST29]

Alternate name: ADMCKD, ADMCKD1, Breast carcinoma associated antigen DF3, Breast carcinoma-associated antigen DF3, CA 15-3, CA15 3, CA15 3 antigen, CA15.3, Cancer antigen 15-3, Carcinoma associated mucin, Carcinoma-associated mucin, CD 227, CD227

Class: Monoclonal

Conjugate: Unconjugated

Description: ST29 distinguishes between sub-species of human INFa and can be used to detect INF oligomers. Neutralises anti-viral activity of INF.

Purpose:

Parental cell:

Organism:

Tissue:

Model:

Gender:

Isotype: IgG1

Reactivity: Human

Selectivity:

Host: Mouse

Immunogen: Human interferon (HuIFN) produced by Namalwa cells (HuIFN-aN)

Immunogen UNIPROT ID:

Sequence:

Growth properties:

Production details:

Formulation:

Recommended controls: PMA stimulated human peripheral blood mononuclear cells

Bacterial resistance:

Selectable markers:

Additional notes:

Target details

Target: Interferon alpha (INFa)

Target alternate names:

Target background: INFa is a type I interferon that is involved in the innate immune response against viral infections.

Molecular weight: 18-25 kDa

Ic50:

Applications

Application: ELISA ; Fn

Application notes:

Handling

Format: Liquid

Concentration: 1 mg/ml

Passage number:

Growth medium:

Temperature:

Atmosphere:

Volume:

Storage medium:

Storage buffer: PBS with 0.02% azide

Storage conditions: -15° C to -25° C

Shipping conditions: Shipping at 4° C

Related tools

Related tools: Anti-MUC1, Recombinant [SM3]

References

References: Geng et al. 2013. Cell Mol Bioeng. 6(2):148-159. PMID: 23805168. ; Targeting

Underglycosylated MUC1 for the Selective Capture of Highly Metastatic Breast Cancer Cells Under Flow. ; Srensen et al. 2006. Glycobiology. 16(2):96-107. PMID: 16207894. ; Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. ; Brockhausen et al. 1995. Eur J Biochem. 233(2):607-17. PMID: 7588808. ; Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. ; Burchell et al. 1993. Epithelial Cell Biol. 2(4):155-62. PMID: 7505698. ; Effect of modification of carbohydrate side chains on the reactivity of antibodies with core-protein epitopes of the MUC1 gene product. ; Burchell et al. 1989. Int J Cancer. 44(4):691-6. PMID: 2477336. ; A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes. ; Burchell et al. 1987. Cancer Res. 47(20):5476-82. PMID: 2443241. ; Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin.

CancerTools.org